Tekla Healthcare Opportunities Fund: management transactions · United States · SEC (Form 4)

About Tekla Healthcare Opportunities Fund

Tekla Healthcare Opportunities Fund is a U.S.-listed closed-end investment fund traded on the NYSE under the ticker THQ. For international investors, it is important to note that THQ is not an operating healthcare company; it is a specialized investment vehicle organized as a Massachusetts business trust and registered as a non-diversified closed-end management investment company. The fund was formed on April 2, 2014 and is headquartered in Boston, Massachusetts, at 100 Federal Street, 19th Floor. Historically part of the Tekla family of healthcare funds, THQ was previously managed by Tekla Capital Management LLC and then transferred to abrdn effective October 27, 2023, which is the most significant recent structural development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1604522/000110465922068023/tm228077d1_ncsrs.htm?utm_source=openai)) From an investment standpoint, Tekla Healthcare Opportunities Fund seeks current income and long-term capital appreciation by investing in companies engaged in the healthcare industry. Its mandate is broad and opportunistic: the fund may allocate across healthcare equities, debt securities, and pooled investment vehicles, with exposure that can extend to biotechnology, healthcare technology, medical devices, and adjacent healthcare-related segments. This broad remit gives the portfolio manager flexibility to shift between sub-industries and capital structures, rather than relying on a single healthcare bet. ([abrdn.com](https://www.abrdn.com/docs?editionid=2bcf5c9d-48e2-4add-b918-b02d0104d164&utm_source=openai)) In competitive terms, THQ occupies a niche within U.S. listed healthcare closed-end funds. Its distinction lies in the combination of a daily traded NYSE listing and an active, income-oriented healthcare strategy. Compared with open-end mutual funds or passive ETFs, a closed-end fund can trade at a discount or premium to net asset value, which introduces a separate valuation dimension that investors should monitor. This structure makes THQ relevant both as a thematic healthcare allocation and as a market-traded income instrument. ([beta.nyse.com](https://beta.nyse.com/products/exchange-traded-products/closed-end-funds?utm_source=openai)) Recent highlights center on the 2023 change of investment adviser to abrdn, which assumed responsibility for THQ and the other former Tekla closed-end funds. Current abrdn materials also show continued quarterly distribution activity, underscoring the fund’s role as a cash-yielding healthcare exposure on the NYSE. For investors in France, Belgium, and Switzerland, THQ should therefore be viewed primarily as a listed U.S. healthcare income fund rather than as a conventional healthcare operator. ([sec.gov](https://www.sec.gov/Archives/edgar/data/805267/000110465924069986/tm2416006d9_ncsrs.htm?utm_source=openai))